Gabapentin had a favorable safety profile and there were no unexpected or serious drug-related adverse events or differences in study discontinuation rates due to adverse events. Of note, somnolence has been a commonly reported adverse event in gabapentin pain and epilepsy trials,42 but was not a common complaint among our alcohol dependent participants. Conversely, prior to treatment our subjects reported experiencing sleep disturbance and related daytime dysfunction that significantly improved with gabapentin relative to placebo. No evidence of drug substitution or misuse of gabapentin was detected.
